Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076830 · ClinicalTrials.gov registry record
Evaluation and Treatment of Patients With Connective Tissue Disease
A clinical trial of Osteogenesis Imperfecta and Bone Diseases, Metabolic, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Completed
- Registry status
- 180
- Enrollment target
- 1
- Study location
NCT00076830 is a study of Osteogenesis Imperfecta and Bone Diseases, Metabolic that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 180 participants, above the 147-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target (22% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00076830, a study of Osteogenesis Imperfecta and Bone Diseases, Metabolic, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- COMPLETED
- Registry status
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
This study offers evaluation and treatment of patients with a suspected connective tissue disorder. The protocol is not designed to test new treatments; rather, patients receive standard care. The study is designed to: 1) allow NICHD's staff to learn more about connective tissue disorders, 2) train physicians in the evaluation and treatment of these disorders; and 3) establish a pool of patients who may be eligible for other NICHD protocols for connective tissue disorders. (Participants in this protocol will not be required to join another study; the decision will be voluntary.) Patients of all ages with a suspected connective tissue disorder and their unaffected family members may be eligible for this study. Participants undergo diagnostic procedures that may include a medical history, physical examination, X-ray studies, eye examinations, and blood drawing, as well as other specialized tests, when needed. Additional tests may include: * Blood test for DNA genetic analysis * Skin biopsy: Removal of a small piece of tissue for microscopic examination. The area of skin selected for the biopsy is numbed and a small circle of skin, usually from the upper arm, is removed with a surgical cookie cutter-like instrument. * Magnetic resonance imaging (MRI): This test uses a strong magnetic field and radio waves to show structural and chemical changes in tissues. The patient lies on a table that slides into a narrow cylinder containing a magnetic field. Ear plugs are worn to muffle loud knocking and thumping sounds that occur with electrical switching of the magnetic fields. * Computed tomography (CT) scans: This test allows the doctor to view the organs inside the body in small sections. The patient lies in a doughnut-like machine. Scanning can be done from different angles, allowing a three dimensional picture of the part of the body being studied. It may be done with or without injection of a contrast material. * Referral to appropriate sub-specialists when potential co
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2004-05-18 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076830
The ClinicalTrials.gov registry entry for NCT00076830 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 147-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target (22% higher). The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Osteogenesis Imperfecta appearing as the primary indexed condition, and to 0 interventions.
NCT00076830 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00076830 about?
NCT00076830 is a clinical study titled "Evaluation and Treatment of Patients With Connective Tissue Disease". This study offers evaluation and treatment of patients with a suspected connective tissue disorder. The protocol is not designed to test new treatments; rather, patients receive standard care. The study is designed to: 1) allow NICHD's staff to learn more about connective tissue disorders, 2) train ...
What is the current status of trial NCT00076830?
This trial is currently completed. The enrollment target is 180 participants. The study started on 2004-05-18.
What conditions does trial NCT00076830 study?
This clinical trial studies the following conditions: Osteogenesis Imperfecta, Bone Diseases, Metabolic, Connective Tissue Disorders, Melorheostosis.
Who is sponsoring clinical trial NCT00076830?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00076830 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteogenesis Imperfecta
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
RECRUITING · Phase 3
-
Effects of Bisphosphonates on OI-Related Hearing Loss
RECRUITING · Phase 4
-
BBD Longitudinal Study of Osteogenesis Imperfecta
RECRUITING
-
Setrusumab vs Placebo for Osteogenesis Imperfecta
ACTIVE NOT RECRUITING · Phase 2
-
Urinary Biomarkers of OI Pathobiology
ACTIVE NOT RECRUITING
-
Clear Aligners for the Treatment of Dental Malocclusion in OI
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.